BR112016019525B1 - Proteína, composição imunogênica que compreende a dita proteína, vacina e uso terapêutico das ditas proteína, composição imunogênica e vacina - Google Patents

Proteína, composição imunogênica que compreende a dita proteína, vacina e uso terapêutico das ditas proteína, composição imunogênica e vacina Download PDF

Info

Publication number
BR112016019525B1
BR112016019525B1 BR112016019525-6A BR112016019525A BR112016019525B1 BR 112016019525 B1 BR112016019525 B1 BR 112016019525B1 BR 112016019525 A BR112016019525 A BR 112016019525A BR 112016019525 B1 BR112016019525 B1 BR 112016019525B1
Authority
BR
Brazil
Prior art keywords
seq
protein
uspa2
amino acids
fact
Prior art date
Application number
BR112016019525-6A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112016019525A2 (pt
Inventor
Normand Blais
Cindy Castado
Patrick Chomez
Marianne Dewerchin
Original Assignee
Glaxosmithkline Biologicals S.A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A filed Critical Glaxosmithkline Biologicals S.A
Publication of BR112016019525A2 publication Critical patent/BR112016019525A2/pt
Publication of BR112016019525B1 publication Critical patent/BR112016019525B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A61K39/1045—Moraxella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1218—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Acinetobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112016019525-6A 2014-02-24 2015-02-20 Proteína, composição imunogênica que compreende a dita proteína, vacina e uso terapêutico das ditas proteína, composição imunogênica e vacina BR112016019525B1 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461943909P 2014-02-24 2014-02-24
US61/943,909 2014-02-24
US201461946937P 2014-03-03 2014-03-03
US201461946932P 2014-03-03 2014-03-03
US61/946,932 2014-03-03
US61/946,937 2014-03-03
PCT/IB2015/051308 WO2015125118A1 (en) 2014-02-24 2015-02-20 Uspa2 protein constructs and uses thereof

Publications (2)

Publication Number Publication Date
BR112016019525A2 BR112016019525A2 (pt) 2017-10-24
BR112016019525B1 true BR112016019525B1 (pt) 2024-01-02

Family

ID=52629643

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016019525-6A BR112016019525B1 (pt) 2014-02-24 2015-02-20 Proteína, composição imunogênica que compreende a dita proteína, vacina e uso terapêutico das ditas proteína, composição imunogênica e vacina

Country Status (28)

Country Link
US (3) US10040832B2 (enExample)
EP (2) EP3498292B1 (enExample)
JP (1) JP6585085B2 (enExample)
KR (1) KR102515835B1 (enExample)
CN (2) CN106061995A (enExample)
AU (1) AU2015220369B2 (enExample)
BE (1) BE1022345A9 (enExample)
BR (1) BR112016019525B1 (enExample)
CA (1) CA2939862C (enExample)
CY (2) CY1121535T1 (enExample)
DK (2) DK3498292T3 (enExample)
EA (1) EA034352B1 (enExample)
ES (2) ES2899300T3 (enExample)
HR (2) HRP20211926T1 (enExample)
HU (2) HUE057505T2 (enExample)
IL (1) IL246994B (enExample)
LT (2) LT3498292T (enExample)
ME (1) ME03335B (enExample)
MX (1) MX376079B (enExample)
PL (2) PL3498292T3 (enExample)
PT (2) PT3498292T (enExample)
RS (2) RS58451B1 (enExample)
SG (1) SG11201606272PA (enExample)
SI (2) SI3498292T1 (enExample)
SM (2) SMT201900166T1 (enExample)
TW (1) TW201620927A (enExample)
UY (1) UY36006A (enExample)
WO (1) WO2015125118A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201620927A (zh) * 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Ｕｓｐａ２蛋白質構築體及其用途
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
JP2020515587A (ja) * 2017-03-31 2020-05-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 免疫原性組成物、使用及び処置方法
US12016919B2 (en) 2017-05-30 2024-06-25 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
JP2020530478A (ja) * 2017-08-14 2020-10-22 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫応答を強化する方法
CA3083078A1 (en) 2017-12-01 2019-06-06 Glaxosmithkline Biologicals Sa Saponin purification
GB201803692D0 (en) * 2018-03-08 2018-04-25 Glaxosmithkline Biologicals Sa Immunogenic composition
EP3833382A1 (en) 2018-08-07 2021-06-16 GlaxoSmithKline Biologicals S.A. Processes and vaccines
JP2021534761A (ja) * 2018-08-23 2021-12-16 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性タンパク質および組成物
WO2020109365A1 (en) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
WO2020212461A1 (en) 2019-04-18 2020-10-22 Glaxosmithkline Biologicals Sa Antigen binding proteins and assays
BR112021024363A2 (pt) 2019-06-05 2022-03-22 Glaxosmithkline Biologicals Sa Purificação de saponina
AU2020325645A1 (en) 2019-08-05 2022-02-17 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2021023692A1 (en) 2019-08-05 2021-02-11 Glaxosmithkline Biologicals Sa Process for preparing a composition comprising a protein d polypeptide
WO2021048159A1 (en) 2019-09-11 2021-03-18 Glaxosmithkline Biologicals Sa Assay
WO2022175423A1 (en) 2021-02-22 2022-08-25 Glaxosmithkline Biologicals Sa Immunogenic composition, use and methods
EP4558170A1 (en) 2022-07-19 2025-05-28 GlaxoSmithKline Biologicals S.A. Continuous process for vaccine production

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
AU685443B2 (en) 1993-03-23 1998-01-22 Smithkline Beecham Biologicals (Sa) Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
DK0772619T4 (da) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
KR100615109B1 (ko) * 1996-12-20 2006-08-22 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 모렉셀라 카타르할리스의 ｕｓｐａ1, ｕｓｐａ2 항원
CA2423487C (en) 2000-09-26 2015-12-15 Hybridon, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
US6942802B2 (en) * 2001-04-13 2005-09-13 Wyeth Holdings Corporation Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography
EP1412381B1 (en) * 2001-07-27 2010-06-02 Novartis Vaccines and Diagnostics S.r.l. Antibodies against meningococcal adhesin app
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
UA95456C2 (ru) * 2005-08-10 2011-08-10 Арне Форсгрен Аб Взаимодействие moraxella catarrhalis с эпителиальными клетками, внеклеточными матриксными белками и системой комплемента
AU2006277076B2 (en) * 2005-08-10 2012-03-29 Arne Forsgren Ab Interaction of Moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system
CA2636566C (en) * 2006-01-17 2018-03-13 Arne Forsgren A novel surface exposed haemophilus influenzae protein (protein e; pe)
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
CA2835510A1 (en) * 2011-05-11 2012-11-15 Riesbeck Healthcare Sweden Ab Protein f - a novel haemophilus influenzae adhesin with laminin and vitronectin binding properties
TW201620927A (zh) * 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Ｕｓｐａ２蛋白質構築體及其用途

Also Published As

Publication number Publication date
AU2015220369B2 (en) 2018-02-01
US20180354996A1 (en) 2018-12-13
EA034352B1 (ru) 2020-01-30
SMT202100728T1 (it) 2022-01-10
LT3498292T (lt) 2021-11-25
US10745449B2 (en) 2020-08-18
CY1124979T1 (el) 2022-11-25
UY36006A (es) 2015-09-30
CA2939862A1 (en) 2015-08-27
KR102515835B1 (ko) 2023-03-31
IL246994A0 (en) 2016-09-29
CY1121535T1 (el) 2020-05-29
DK3498292T3 (da) 2022-01-03
BR112016019525A2 (pt) 2017-10-24
ME03335B (me) 2019-10-20
KR20160124774A (ko) 2016-10-28
HUE057505T2 (hu) 2022-05-28
LT3110438T (lt) 2019-04-10
SI3110438T1 (sl) 2019-05-31
WO2015125118A1 (en) 2015-08-27
US10040832B2 (en) 2018-08-07
US10947280B2 (en) 2021-03-16
CA2939862C (en) 2022-12-06
EP3498292B1 (en) 2021-10-20
ES2715674T3 (es) 2019-06-05
EP3110438A1 (en) 2017-01-04
PT3498292T (pt) 2021-11-18
HUE042054T2 (hu) 2019-06-28
MX376079B (es) 2025-03-07
JP6585085B2 (ja) 2019-10-02
US20170008932A1 (en) 2017-01-12
HRP20211926T1 (hr) 2022-03-18
AU2015220369A1 (en) 2016-09-15
CN111499701A (zh) 2020-08-07
EA201691611A1 (ru) 2016-12-30
BE1022345A9 (fr) 2016-11-16
BE1022345B1 (fr) 2016-03-25
JP2017507181A (ja) 2017-03-16
RS62592B1 (sr) 2021-12-31
US20200325184A1 (en) 2020-10-15
MX2016010954A (es) 2016-11-11
DK3110438T3 (en) 2019-03-25
SG11201606272PA (en) 2016-09-29
SMT201900166T1 (it) 2019-05-10
EP3498292A1 (en) 2019-06-19
PL3498292T3 (pl) 2022-02-14
CN106061995A (zh) 2016-10-26
PT3110438T (pt) 2019-03-29
SI3498292T1 (sl) 2022-01-31
EP3110438B1 (en) 2019-01-02
ES2899300T3 (es) 2022-03-10
IL246994B (en) 2020-11-30
RS58451B1 (sr) 2019-04-30
TW201620927A (zh) 2016-06-16
PL3110438T3 (pl) 2019-06-28
HRP20190412T1 (hr) 2019-04-19

Similar Documents

Publication Publication Date Title
US10947280B2 (en) UspA2 protein constructs and uses thereof
JP6196963B2 (ja) インフルエンザ菌タンパク質ｅおよびピリンａを含む融合タンパク質および組合せワクチン
BR112015014727B1 (pt) Composição imunogênica, uso de uma composição imunogênica, e, método para prevenir ou tratar a doença c.difficile
US7935354B2 (en) Generation of new BCG vaccine strains protecting against the establishment of latent Mycobacterium tuberculosis infection and reactivation from the latent or persistent state
JP2023098935A (ja) 歯周炎ワクチンおよび関連組成物ならびに使用方法
US11103568B2 (en) Pneumococcal vaccine formulations
ES2367128T3 (es) Procedimiento para preparar una variante del antígeno protector de superficie de erysipelothrix rhusiopathiae en e. coli.
US20240228549A1 (en) Prefusion-stabilized lassa virus glycoprotein complex and its use
US20150291669A1 (en) Recombinant Mycobacterium Encoding A Heparin-Binding Hemagglutinin (HBHA) Fusion Protein And Uses Thereof
BR112016030096B1 (pt) Composição imunogênica, vacina, e, uso de uma composição imunogênica ou de uma vacina
JP2022527206A (ja) 侵入プラスミド抗原ｂの最適化された無細胞合成、および関連する組成物、および使用方法
CN102448488A (zh) 支原体感染症用疫苗
CN116940372A (zh) 流感嗜血杆菌疫苗和使用方法
JP2018134074A (ja) ヘパリン結合性赤血球凝集素（ｈｂｈａ）融合タンパク質とその用途をコードする組換え型マイコバクテリウム

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/02/2015, OBSERVADAS AS CONDICOES LEGAIS

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 11A ANUIDADE.